Literature DB >> 4009754

Deep venous thrombosis and pulmonary embolism in patients with acute spinal cord injury: a comparison with nonparalyzed patients immobilized due to spinal fractures.

P Myllynen, M Kammonen, P Rokkanen, O Böstman, M Lalla, E Laasonen.   

Abstract

The occurrence of deep venous thrombosis (DVT) was studied in the series of 23 consecutive patients with acute spinal cord injury and 14 immobilized patients with spinal fractures without paralysis. The incidence of DVT in paralyzed patients was 100% as detected by the 125I-labeled fibrinogen test and confirmed by contrast venography, and 64% as detected by repeated clinical examinations and confirmed by contrast venography. The respective incidence of DVT in nonparalyzed patients with spinal fractures was 0%. The diagnosis of DVT was reached earlier with the radiofibrinogen test than with the clinical followup (5 days vs. 25 days). Two of the 23 paralyzed patients (9%) developed nonfatal clinical pulmonary embolism (PE). There were no differences in the values of routine coagulation tests. The result justifies prophylactic anticoagulant therapy in all cases of spinal cord injury during the acute post-traumatic phase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4009754     DOI: 10.1097/00005373-198506000-00013

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  10 in total

Review 1.  Management of Deep Vein Thrombosis (DVT) Prophylaxis in Trauma Patients.

Authors:  Shahram Paydar; Golnar Sabetian; Hosseinali Khalili; Javad Fallahi; Mohammad Tahami; Bizhan Ziaian; Hamid Reza Abbasi; Shahram Bolandparvaz; Fariborz Ghaffarpasand; Zahra Ghahramani
Journal:  Bull Emerg Trauma       Date:  2016-01

2.  Prevention of Venous Thromboembolism in Individuals with Spinal Cord Injury: Clinical Practice Guidelines for Health Care Providers, 3rd ed.: Consortium for Spinal Cord Medicine.

Authors: 
Journal:  Top Spinal Cord Inj Rehabil       Date:  2016

Review 3.  Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations.

Authors:  M T Nurmohamed; H ten Cate; J W ten Cate
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

4.  Incidence, risk factors and clinical course of pyogenic spondylodiscitis patients with pulmonary embolism.

Authors:  Daniel Dubinski; Sae-Yeon Won; Fee Keil; Bedjan Behmanesh; Max Dosch; Peter Baumgarten; Joshua D Bernstock; Volker Seifert; Thomas M Freiman; Florian Gessler
Journal:  Eur J Trauma Emerg Surg       Date:  2021-09-02       Impact factor: 2.374

5.  Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study.

Authors:  Scott Worley; Christine Short; Jeff Pike; David Anderson; Jo-Anne Douglas; Kara Thompson
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

6.  Venous thromboembolism in acute spinal cord injury patients.

Authors:  Shyam K Saraf; Raj Jb Rana; Om P Sharma
Journal:  Indian J Orthop       Date:  2007-07       Impact factor: 1.251

7.  Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank.

Authors:  M Margaret Knudson; Danagra G Ikossi; Linda Khaw; Diane Morabito; Larisa S Speetzen
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

8.  Deep vein thrombosis prophylaxis in trauma patients.

Authors:  Serdar Toker; David J Hak; Steven J Morgan
Journal:  Thrombosis       Date:  2011-05-15

9.  Admission Prevalence and Risk Factors of Deep Vein Thrombosis in Patients with Spinal Cord Injury Complicated with Cervical Fractures.

Authors:  Bing Lv; Haiying Wang; Weifeng Li; Gefeng Han; Xiangdong Liu; Cheng Zhang; Zipeng Zhang
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

10.  Pulmonary Embolism After Acute Spinal Cord Injury and COVID-19.

Authors:  Thomas John Pisano; Jaclyn Joki; Beverly Hon; Sara Cuccurullo
Journal:  Am J Phys Med Rehabil       Date:  2020-11       Impact factor: 3.412

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.